Utility of the global CDR ® plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium.

DISCUSSION: The global CDR plus NACC FTLD score could be an attractive outcome measure for clinical trials in symptomatic FTLD, and may be useful in natural history studies and clinical trials in FTLD spectrum disorders. PMID: 31914218 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/31914218?dopt=Abstract

Source: The Journal of Alzheimers Association - January 9, 2020 Category: Psychiatry Tags: Alzheimers Dement Source Type: research